Clinical, physiological, and radiological features of asthma–chronic obstructive pulmonary disease overlap syndrome

International Journal of COPD

Volumn 10, Issue , 2015, Pages 947-954

  Suzuki, Toshio ^a   Tada, Yuji ^a   Kawata, Naoko ^a   Matsuura, Yukiko ^a   Ikari, Jun ^a   Kasahara, Yasunori ^a   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Budesonide formoterol; Cross sectional area (CSA); Percentage of wall area (WA ); Pulmonary vessels

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT;

AGED; AIRWAY WALL THICKNESS; ARTICLE; ASTHMA; ASTHMA CHRONIC OBSTRUCTIVE LUNG DISEASE OVERLAP SYNDROME; ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; BLOOD VESSEL WALL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG BLOOD VESSEL; LUNG DIFFUSING CAPACITY FOR CARBON MONOXIDE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; RESIDUAL VOLUME; RESPIRATORY TRACT DISEASE ASSESSMENT; RESPIRATORY TRACT PARAMETERS; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; TREATMENT DURATION; COMPARATIVE STUDY; CONVALESCENCE; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VEIN; SYNDROME; TIME FACTOR; TREATMENT OUTCOME; VASCULARIZATION;

ADMINISTRATION, INHALATION; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VEINS; RECOVERY OF FUNCTION; RESPIRATORY FUNCTION TESTS; SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929394171     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S80022     Document Type: Article

References (30)

1. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2000;160(11):1683–1689.
2. Kauppi P, Kupiainen H, Lindqvist A, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48(3):279–285.
3. Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013;107(7):1053–1060.
4. Rhee CK, Yoon HK, Yoo KH, et al. Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD. 2014;11(2):163–170.
5. Chung JW, Kong KA, Lee JH, Lee SJ, Ryu YJ, Chang JH. Characteristics and self-rated health of overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2014;9:795–804.
6. Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease. Asthma COPD and Asthma–COPD Overlap Syndrome (ACOS); 2015. Available from: http://www.ginasthma.org/local/uploads/files/AsthmaCOPDOverlap.pdf. Accessed March 10, 2015.
7. Detoraki A, Granata F, Staibano S, Rossi FW, Marone G, Genovese A. Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy. 2010;65(8):946–958.
8. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med. 1997;156(1):229–233.
9. Feltis BN, Wignarajah D, Reid DW, Ward C, Harding R, Walters EH. Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax. 2007;62(4):314–319.
10. Hoshino M, Nakamura Y, Sim JJ, et al. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin Exp Allergy. 1998;28(5):568–577.
11. Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH. Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax. 1999;54(4):289–295.
12. Calverley P, Pauwels R, Vestbo J, et al; Trial of Inhaled STeroids ANd Long-Acting Beta2 Agonists Study Group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456.
13. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(1):74–81.
14. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245): 1297–1303.
15. Matsuura Y, Kawata N, Yanagawa N, et al. Quantitative assessment of cross-sectional area of small pulmonary vessels in patients with COPD using inspiratory and expiratory MDCT. Eur J Radiol. 2013;82(10):1804–1810.
16. Yahaba M, Kawata N, Iesato K, et al. The effects of emphysema on airway disease: correlations between multi-detector CT and pulmonary function tests in smokers. Eur J Radiol. 2014;83(6):1022–1028.
17. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2009;63(4):1–121.
18. American Thoracic Society/European Respiratory Society Task Force. Standards for the Diagnosis and Management of Patients with COPD. Version 1.2. New York: American Thoracic Society; 2004.
19. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64(8):728–735.
20. Committee of Respiratory Physiology in Japanese Respiratory Society. [Guideline of respiratory function tests-spirometry, flow-volume curve, diffusion capacity of the lung]. Nihon Kokyuki Gakkai Zasshi. 2004:1–56. Japanese.
21. Coche E, Pawlak S, Dechambre S, Maldague B. Peripheral pulmonary arteries: identification at multi-slice spiral CT with 3D reconstruction. Eur Radiol. 2003;13(4):815–822.
22. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2014 (Revision); 2015. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2014_Aug12.pdf. Accessed March 10, 2015.
23. Hardin M, Silverman EK, Barr RG, et al; COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127.
24. Nakano Y, Wong JC, de Jong PA, et al. The prediction of small airway dimensions using computed tomography. Am J Respir Crit Care Med. 2005;171(2):142–146.
25. Matsuoka S, Yamashiro T, Matsushita S, et al. Usefulness of coronal reconstruction CT images for quantitative evaluation of the cross-sectional area of small pulmonary vessels. Acad Radiol. 2014;21(11):1411–1415.
26. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106(11):1311–1319.
27. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001;163(3 pt 1):737–744.
28. Barr RG, Mesia-Vela S, Austin JH, et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007;176(12):1200–1207.
29. Shigeta A, Tada Y, Wang JY, et al. CD40 amplifies Fas-mediated apoptosis: a mechanism contributing to emphysema. Am J Physiol Lung Cell Mol Physiol. 2012;303(2):141–151.
30. Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res. 2010;11:132.